Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilitiesNess Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), NASDAQ:NXTS (“Nexentis” or the “Company”), a drug discovery company that also invests in…